🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

195 results for “Boehringer Ingelheim” Clear

  1. fixed dose combination of telmisartan+amlodipine

    Boehringer Ingelheim

    Hypertension

    phase 3 small molecule completed

    1 trial

  2. linagliptine 5 mg

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  3. nintedanib, Nintedanib, nintedanib

    Boehringer Ingelheim

    Childhood Interstitial Lung Disease

    phase 3 small molecule active

    1 trial

  4. obrixtamig

    Boehringer Ingelheim

    Small Cell Lung Cancer (SCLC)

    phase 3 small molecule active

    1 trial

  5. placebo

    Boehringer Ingelheim

    Pulmonary Fibrosis

    phase 3 small molecule completed

    1 trial

  6. placebo plus docetaxel

    Boehringer Ingelheim

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule completed

    1 trial

  7. survodutide

    Boehringer Ingelheim

    Obesity

    phase 3 other active

    1 trial

  8. telmisartan/amlodipine 40/5 mg fixed combination

    Boehringer Ingelheim

    Hypertension

    phase 3 small molecule completed

    1 trial

  9. tiotropium

    Boehringer Ingelheim

    Pulmonary Disease, Chronic Obstructive

    phase 3 small molecule completed

    1 trial

  10. tiotropium + olodaterol

    Boehringer Ingelheim

    Pulmonary Disease, Chronic Obstructive

    phase 3 small molecule completed

    1 trial

  11. tiotropium 5mcg/day

    Boehringer Ingelheim

    Asthma

    phase 3 small molecule completed

    1 trial

  12. tiotropium high dose

    Boehringer Ingelheim

    Asthma

    phase 3 small molecule completed

    1 trial

  13. warfarin

    Boehringer Ingelheim

    Atrial Fibrillation

    phase 3 small molecule completed

    1 trial

  14. zongertinib

    Boehringer Ingelheim

    Lung Cancer, Non-squamous, Non-small Cell

    phase 3 small molecule active

    1 trial

  15. A Phase II, 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in patients with major depressive disorder

    Boehringer Ingelheim

    Major depressive disorder

    phase 2 other active

    1 trial

  16. Afatinib once daily (OD)

    Boehringer Ingelheim

    Breast Neoplasms

    phase 2 small molecule completed

    1 trial

  17. Avenciguat

    Boehringer Ingelheim

    Chronic Kidney Disease

    phase 2 small molecule completed

    1 trial

  18. BI 1744 CL 2 µg

    Boehringer Ingelheim

    Pulmonary Disease, Chronic Obstructive

    phase 2 small molecule completed

    1 trial

  19. BI 1810631

    Boehringer Ingelheim

    HER2-mutated or overexpressed/amplified solid tumours

    phase 2 small molecule active

    1 trial

  20. BI 1815368, BI 1815368 Placebo, BI 1815368

    Boehringer Ingelheim

    Centre-involved diabetic macular edema

    phase 2 small molecule active

    1 trial

  21. BI 1819479, Placebo, Film-coated tablet, matching in size, weight, colour and shape to BI 1819479 (both unit strengths), BI 1819479

    Boehringer Ingelheim

    idiopathic pulmonary fibrosis

    phase 2 small molecule active

    1 trial

  22. BI 1839100, Placebo matching in size, weight, colour and shape to tablets of BI 1839100

    Boehringer Ingelheim

    Progressive pulmonary fibrosis (PPF), Idiopathic pulmonary fibrosis (IPF)

    phase 2 small molecule active

    1 trial

  23. BI 3000202, BI 3000202, Placebo matching BI 3000202

    Boehringer Ingelheim

    Systemic lupus erythematosus

    phase 2 small molecule active

    1 trial

  24. BI 3720931, BI 3720931

    Boehringer Ingelheim

    Cystic fibrosis

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources